The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes
Open accessAbstract
BACKGROUND: Mutations in the tumor protein 53 (TP53) gene predict a poor prognosis in patients with acute myeloid leukemia (AML). METHODS: Peripheral blood or bone marrow samples from 293 patients with newly diagnosed AML were analyzed with targeted, amplicon‐based, next‐generation sequencing‐based mutation analysis. RESULTS: TP53 mutations were identified in 53 patients (18%; 45 were missense mutations). In 13 of the 53 patients, the most common pattern of amino acid substitution was a substitution of arginine to histidine on different codons. The clinical characteristics, pattern of mutations, response to different therapies, and outcomes of patients with AML‐TP53–mutated (n = 53) versus wild‐type TP53 (n = 240) were compared. TP53 mutations were significantly more likely in patients who had a complex karyotype; abnormalities of chromosome 5, 7, and 17; and therapy‐related AML. Patients who had TP53‐mutated AML had significantly lower incidence of mutations in Fms‐like tyrosine kinase 3 (FLT3), rat sarcoma (RAS), and nucleophosmin (NPM1) and higher incidence of coexisting MPL mutations compared with those who had wild type TP53. The distribution of TP53 mutations was equal for both age groups (ages <60 years vs ≥60 years). TP53‐mutated AML was associated with a lower complete remission rate (41% vs 57%; P = .04), a significantly inferior complete remission duration (at 2 years: 30% vs 55%; P = .001), and overall survival (at 2 years: 9% vs 24%; P ≤ .0001) irrespective of age or the type of treatment received (high‐intensity vs low‐intensity chemotherapy). CONCLUSIONS: The type of treatment received did not improve outcomes in younger or older patients with TP53‐mutated AML. These data suggest that novel therapies are needed to improve the outcome of patients with AML who have TP53 mutations. Cancer 2016;122:3484–3491. © 2016 American Cancer Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551 · cited 2×
“46 Platelets, 10(3)/lL 32 (4-153) 39 (1-708) .”
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · cited 2×
“46 Platelets, 10(3)/lL 32 (4-153) 39 (1-708) .”
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,946
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
Wong, T. N., Ramsingh, G., Young, A. L., Miller, C. A., Touma, W., Welch, J. S., Lamprecht, T. L., Shen, D., Hundal, J., Fulton, R. S., et al. (2015) · Nature · doi:10.1038/nature13968 · Cited by 892
Rücker, F. G., Schlenk, R. F., Bullinger, L., Kayser, S., Teleanu, V., Kett, H., Habdank, M., Kugler, C.-M., Holzmann, K., Gaidzik, V. I., et al. (2012) · Blood · doi:10.1182/blood-2011-08-375758 · Cited by 683
Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal, A., & Rotter, V. (2000) · PubMed · Cited by 666
p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM
Song, H., Hollstein, M., & Xu, Y. (2007) · Nature Cell Biology · doi:10.1038/ncb1571 · Cited by 439
FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia
Stirewalt, D. L., Kopecky, K. J., Meshinchi, S., Appelbaum, F. R., Slovak, M. L., Willman, C. L., & Radich, J. P. (2001) · Blood · doi:10.1182/blood.v97.11.3589 · Cited by 431
Christiansen, D. H., Andersen, M. K., & Pedersen-Bjergaard, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1405 · Cited by 308
Mouse models of human AML accurately predict chemotherapy response
Zuber, J., Radtke, I., Pardee, T. S., Zhao, Z., Rappaport, A. R., Luo, W., McCurrach, M. E., Yang, M.-M., Dolan, M. E., Kogan, S. C., et al. (2009) · Genes & Development · doi:10.1101/gad.1771409 · Cited by 279
p53 mutation heterogeneity in cancer
Soussi, T., & Lozano, G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.190 · Cited by 275
Haferlach, C., Dicker, F., Herholz, H., Schnittger, S., Kern, W., & Haferlach, T. (2008) · Leukemia · doi:10.1038/leu.2008.143 · Cited by 247
Genetics of therapy-related myelodysplasia and acute myeloid leukemia
Pedersen-Bjergaard, J., Andersen, M. K., Andersen, M. T., & Christiansen, D. H. (2008) · Leukemia · doi:10.1038/sj.leu.2405078 · Cited by 232
Bowen, D., Groves, M. J., Burnett, A. K., Patel, Y., Allen, C., Green, C., Gale, R. E., Hills, R., Linch, D. C., & on behalf of the Medical Research Council Adult Leukaemia Working Party, U. (2009) · Leukemia · doi:10.1038/leu.2008.173 · Cited by 214
Schoch, C., Kern, W., Kohlmann, A., Hiddemann, W., Schnittger, S., & Haferlach, T. (2005) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20193 · Cited by 188
Hou, H.-A., Chou, W.-C., Kuo, Y.-Y., Liu, C.-Y., Lin, L.-I., Tseng, M.-H., Chiang, Y.-C., Liu, M.-C., Liu, C.-W., Tang, J.-L., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.59 · Cited by 164
The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia
Seifert, H., Mohr, B., Thiede, C., Oelschlägel, U., Schäkel, U., Illmer, T., Soucek, S., Ehninger, G., Schaich, M., & on behalf of the Study Alliance Leukemia (SAL) (2009) · Leukemia · doi:10.1038/leu.2008.375 · Cited by 158
Mutant p53 protein expression interferes with p53-independent apoptotic pathways
Li, R., Sutphin, P. D., Schwartz, D., Matas, D., Almog, N., Wolkowicz, R., Goldfinger, N., Pei, H., Prokocimer, M., & Rotter, V. (1998) · Oncogene · doi:10.1038/sj.onc.1201867 · Cited by 140
Ok, C. Y., Patel, K. P., Garcia‐Manero, G., Routbort, M. J., Fu, B., Tang, G., Goswami, M., Singh, R. R., Kanagal‐Shamanna, R., Pierce, S. A., et al. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.12.006 · Cited by 125
Self-citationMutant p53: Multiple Mechanisms Define Biologic Activity in Cancer
Kim, M., Zhang, Y., & Lozano, G. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00249 · Cited by 117
Middeke, J. M., Herold, S., Rücker‐Braun, E., Berdel, W. E., Stelljes, M., Kaufmann, M., Schäfer‐Eckart, K., Baldus, C. D., Stuhlmann, R., Ho, A. D., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13912 · Cited by 101
Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia
Parkin, B. L., Erba, H. P., Ouillette, P. D., Roulston, D., Purkayastha, A. A., Karp, J. E., Talpaz, M., Kujawski, L. A., Shakhan, S., Li, C., et al. (2010) · Blood · doi:10.1182/blood-2010-01-266999 · Cited by 75
Immunotherapeutic strategies for relapse control in acute myeloid leukemia
Martner, A., Thorén, F. B., Aurelius, J., & Hellstrand, K. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.06.006 · Cited by 75
Ånensen, N., Hjelle, S. M., Belle, W. V., Haaland, I., Silden, E., Bourdon, J., Hovland, R., Taskén, K., Knappskog, S., Lønning, P. E., et al. (2011) · Oncogene · doi:10.1038/onc.2011.348 · Cited by 67
TP53 mutations in older adults with acute myeloid leukemia
Yanada, M., Yamamoto, Y., Iba, S., Okamoto, A., Inaguma, Y., Tokuda, M., Morishima, S., Kanie, T., Mizuta, S., Akatsuka, Y., et al. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-1942-1 · Cited by 37
Nahi, H., Lehmann, S., Bengtzén, S., Jansson, M., Möllgård, L., Paul, C., & Merup, M. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701861645 · Cited by 34
Goh, A. M., Xue, Y., Leushacke, M., Li, L., Wong, J. S., Chiam, P. C., Rahmat, S. A. B., Mann, M. B., Mann, K. M., Barker, N., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4956 · Cited by 28
Cited by
Short, N. J., Rytting, M. E., & Cortes, J. E. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31041-9 · Cited by 781
Self-citationAcute myeloid leukemia: current progress and future directions
Kantarjian, H., Kadia, T., DiNardo, C., Daver, N., Borthakur, G., Jabbour, E., Garcia-Manero, G., Konopleva, M., & Ravandi, F. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00425-3 · Cited by 776
Self-citationSomatic mutations precede acute myeloid leukemia years before diagnosis
Desai, P., Mencia-Trinchant, N., Savenkov, O., Simon, M. S., Cheang, G., Lee, S., Samuel, M., Ritchie, E. K., Guzman, M. L., Ballman, K. V., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0081-z · Cited by 619
Advances in acute myeloid leukemia
Newell, L. F., & Cook, R. J. (2021) · BMJ · doi:10.1136/bmj.n2026 · Cited by 440
Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges
Short, N. J., Konopleva, M., Kadia, T. M., Borthakur, G., Ravandi, F., DiNardo, C. D., & Daver, N. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1011 · Cited by 368
Self-citation
Metadata
- Authors
- Kadia, T. M., Jain, P., Ravandi, F., Garcia‐Manero, G., Andreef, M., Takahashi, K., Borthakur, G., Jabbour, E., Konopleva, M., Daver, N. G., Dinardo, C., Pierce, S., Kanagal‐Shamanna, R., Patel, K., Estrov, Z., Cortes, J., & Kantarjian, H. M.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2016-07-26
- Volume
- 122
- Issue
- 22
- Pages
- 3484-3491
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2499799649
- Cited by
- 261
- References
- 27
- FWCI
- 13.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.